KBC Group
ADPT icon

KBC Group’s Adaptive Biotechnologies ADPT Stock Holding History

KBC Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70K Hold
3,267
– – ﹤0.01% 1587
2026
Q1 		$45K Buy
+3,267
New +$52.1K ﹤0.01% 1683
2025
Q2 		– Sell
-8,378
Closed -$62K – 1715
2025
Q1 		$62K Hold
8,378
– – ﹤0.01% 1720
2024
Q4 		$50K Buy
+8,378
New +$46.2K ﹤0.01% 1813

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

KBC Group's ADPT Position: Q2 2026 in Review

KBC Group held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 3,267 shares worth $70K. The position accounts for ﹤0.01% of the portfolio, ranked #1587.

KBC Group first reported a position in ADPT in Q4 2024 and has held it in 4 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • KBC Group held 3,267 shares of Adaptive Biotechnologies worth $70K as of Q2 2026.
  • KBC Group left its Adaptive Biotechnologies share count unchanged in Q2 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1587 holding.
  • KBC Group first reported a position in Adaptive Biotechnologies in Q4 2024 and has held it in 4 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.